Fig. 5

I (A) Overall survival in patients with JUNB-positive CTCs compared to JUNB-negative patients (p = 0.02, Kaplan-Meier analysis). In the group of patients harboring JUNB-positive CTCs, 90% died during follow-up period vs 75% of deaths in the cohort of patients without JUNB expression. I (B) Kaplan-Meier analysis revealed that the progression-free survival in patients harboring JUNB-positive CTCs was statistically lower compared to patients without JUNB expression (p = 0.015). Patients without JUNB-positive CTCs experienced longer PFS vs JUNB-negative patients [3.5 (range 0–30) vs 9 (range 0–72) months]. II (A) JUNB staining in primary tumor obtained from BC patient. JUNB-positive tumor cells (brown) were very rare in the sample. Inner frame is shown control sample from a squamous cell carcinoma (magnification × 40). II (B) JUNB staining in metastatic tumor obtained from mBC patient. The majority of the tumor cells were positive for JUNB (magnification × 40)